Back

Expert panelists reflect on the selection and use of recently approved treatments, including interleukin pathway inhibitors, for type 2 inflammation in atopic dermatitis.

Management of Type 2 Inflammation in Atopic Dermatitis

Episodes

Specialty:

All

Year:

All

EP. 1: An Overview of Type 2 Inflammation and Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 11th 2022

Shared insight on the nature of inflammation in conjunction with atopic dermatitis with special considerations for possible contributors and severity of disease.

EP. 2: Assessing Impact of AD on Quality of Life

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 11th 2022

Expert perspectives on assessing quality of life when discussing atopic dermatitis and inflammatory disease with patients.

EP. 3: Role of Guidelines and Shared-Decision Making in Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

A panel of experts discuss role of guidelines and importance of shared-decision making in managing patients with atopic dermatitis.

EP. 4: Selecting Therapy for Atopic Dermatitis: Topical Treatment Options

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Moving on to discuss treatment options for patients with atopic dermatitis, experts reflect on optimal use of topical agents in this setting.

EP. 5: Overview of Systemic Therapy Options for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Shared insight on the systemic treatment armamentarium for atopic dermatitis and how it has evolved in recent years.

EP. 6: Atopic Dermatitis: Treating Mild-to-Moderate vs Moderate-to-Severe Disease

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Considerations for managing mild-to-moderate versus moderate-to-severe atopic dermatitis and which therapies are appropriate in each setting.

EP. 7: Managing Atopic Dermatitis During the COVID-19 Pandemic

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

A brief discussion on how the coronavirus 2019 pandemic has impacted the management of patients with atopic dermatitis.

EP. 8: Interleukin Pathway Inhibitors for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Expert perspectives on the interleukin pathway inhibitors, dupilumab and tralokinumab, and their role in managing atopic dermatitis.

EP. 9: JAK Inhibitors for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

EP. 10: Atopic Dermatitis: Breaking Down the AE Profile of JAK Inhibitors

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

EP. 11: Optimal Sequencing of Therapy for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.